Recent data have shown that a combination approach of drugs targeting the function of CXCR4 and PD-L1 enhances the efficacy of anti-PD-L1 therapy in TNBC by preventing two important signaling pathways of tumor proliferation [64]. This evidence concerns the gene CXCR4 and neoplasm.